The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing the molecular landscape of early onset and average onset prostate cancer.
 
Ifeanyichukwu Ogobuiro
No Relationships to Disclose
 
Sachin Deshmukh
No Relationships to Disclose
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Joanne Xiu
No Relationships to Disclose
 
Phillip Walker
Employment - Caris Life Sciences
 
Umang Swami
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Exelixis; Imvax; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); Seattle Genetics/Astellas (Inst)
 
Matthew James Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Chadi Nabhan
No Relationships to Disclose
 
Matthew Abramowitz
Consulting or Advisory Role - Varian Medical Systems
Research Funding - Varian Medical Systems (Inst); Varian Medical Systems (Inst)
 
Alan Pollack
No Relationships to Disclose
 
Alan Dal Pra
Employment - University of Miami Hospitals and Clinics
Leadership - University of Miami
Consulting or Advisory Role - Merck; Pfizer
Research Funding - Veracyte (Inst)
 
Sanoj Punnen
No Relationships to Disclose
 
Brandon A Mahal
Honoraria - Cancer Study Group
Speakers' Bureau - Myovant Sciences
Other Relationship - American Society for Radiation Oncology; Department of Defense-Prostate Cancer Research Program; Prostate Cancer Foundation